Subcutaneous Insulin-Like Growth Factor-1 Treatment in Spinocerebellar Ataxias: An Open Label Clinical Trial

被引：27

作者：

Arpa, Javier ^{[1
]}

Sanz-Gallego, Irene ^{[1
]}

Medina-Baez, Josmarlin ^{[1
]}

Cruz Portela, Luis Valmor ^{[2
]}

Jardim, Laura Bannach ^{[3
,4
,5
]}

Torres-Aleman, Ignacio ^{[7
,8
]}

Morales Saute, Jonas Alex ^{[2
,4
,6
]}

机构：

[1] HULP, Neurol Serv, Madrid, Spain

[2] Univ Fed Rio Grande do Sul, Dept Biochem, Porto Alegre, RS, Brazil

[3] Univ Fed Rio Grande do Sul, Dept Internal Med, Porto Alegre, RS, Brazil

[4] Univ Fed Rio Grande do Sul, Postgrad Program Med Sci, Porto Alegre, RS, Brazil

[5] HCPA, Med Genet Serv, Porto Alegre, RS, Brazil

[6] HCPA, Neurol Serv, Porto Alegre, RS, Brazil

[7] CSIC, Inst Cajal, Lab Cellular & Mol Neuroendocrinol, E-28002 Madrid, Spain

[8] CIBERNED, Madrid, Spain

来源：

MOVEMENT DISORDERS | 2011年 / 26卷 / 02期

关键词：

DISEASE; MICE;

D O I：

10.1002/mds.23423

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：358 / 359

页数：2

共 7 条

[1] Insulin and neurodegenerative disease: shared and specific mechanisms [J].

Craft, S ;

Watson, GS .

LANCET NEUROLOGY, 2004, 3 (03) :169-178

[2] Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice [J].

Emamian, ES ;

Kaytor, MD ;

Duvick, LA ;

Zu, T ;

Tousey, SK ;

Zoghbi, HY ;

Clark, HB ;

Orr, HT .

NEURON, 2003, 38 (03) :375-387

[3] Responsiveness of different rating instruments in spinocerebellar ataxia patients [J].

Schmitz-Huebsch, T. ;

Fimmers, R. ;

Rakowicz, M. ;

Rola, R. ;

Zdzienicka, E. ;

Fancellu, R. ;

Mariotti, C. ;

Linnemann, C. ;

Schoels, L. ;

Timmann, D. ;

Filla, A. ;

Salvatore, E. ;

Infante, J. ;

Giunti, P. ;

Labrum, R. ;

Kremer, B. ;

van de Warrenburg, B. P. C. ;

Baliko, L. ;

Melegh, B. ;

Depondt, C. ;

Schulz, J. ;

du Montcel, S. Tezenas ;

Klockgether, T. .

NEUROLOGY, 2010, 74 (08) :678-684

[4] Autosomal dominant cerebellar ataxias:: clinical features, genetics, and pathogenesis [J].

Schöls, L ;

Bauer, P ;

Schmidt, T ;

Schulte, T ;

Riess, O .

LANCET NEUROLOGY, 2004, 3 (05) :291-304

[5] Subcutaneous IGF-1 is not beneficial in 2-year ALS trial [J].

Sorenson, E. J. ;

Windbank, A. J. ;

Mandrekar, J. N. ;

Bamlet, W. R. ;

Appel, S. H. ;

Armon, C. ;

Barkhaus, P. E. ;

Bosch, P. ;

Boylan, K. ;

David, W. S. ;

Feldman, E. ;

Glass, J. ;

Gutmann, L. ;

Katz, J. ;

King, W. ;

Luciano, C. A. ;

McCluskey, L. F. ;

Nash, S. ;

Newman, D. S. ;

Pascuzzi, R. M. ;

Pioro, E. ;

Sams, L. J. ;

Scelsa, S. ;

Simpson, E. P. ;

Subramony, S. H. ;

Tiryaki, E. ;

Thornton, C. A. .

NEUROLOGY, 2008, 71 (22) :1770-1775

[6] Intranasal administration of IGF-I improves behavior and Purkinje cell pathology in SCA1 mice [J].

Vig, PJS ;

Subramony, SH ;

D'Souza, DR ;

Wei, J ;

Lopez, ME .

BRAIN RESEARCH BULLETIN, 2006, 69 (05) :573-579

[7] Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway [J].

Yamamoto, A ;

Cremona, ML ;

Rothman, JE .

JOURNAL OF CELL BIOLOGY, 2006, 172 (05) :719-731

← 1 →